Solta Medical Inc (SLTM), Keryx Biopharmaceuticals (KERX): Two Stocks to Buy on Merger Speculation

Page 1 of 2

Large healthcare companies are facing revenue declines due to expiring patents. These cash rich giants are increasingly investing in small biotechnology companies with promising candidates. Solta Medical Inc (NASDAQ:SLTM) and Keryx Biopharmaceuticals (NASDAQ:KERX) are good targets for Big Pharma players looking to diversify or expand patent portfolios.

Solta Medical Inc (NASDAQ:SLTM)

Solta Medical Inc (NASDAQ:SLTM)’s board is resisting an acquisition but it seems highly likely that activist shareholders will succeed. The shareholders have already rejected the Board’s attempts to double outstanding shares and reduce chances of acquisition. Keryx is getting ready to submit its first NDA next month and there is a high probability that it will get FDA approval for Zerenex.

Medical Equipment

Solta Medical Inc (NASDAQ:SLTM) is involved in design, development and commercialization of energy-based medical appliance and equipment. Its target market expands to Middle East, North America, Europe and Asia Pacific. Solta Medical Inc (NASDAQ:SLTM) brands include Fraxel, Thermage, Liposonix, Isolaz and CLARO. Over the years it has developed its own distribution network but also utilizes independent distributors and retail networks. Solta Medical Inc (NASDAQ:SLTM)’s customers include gynecologists, dermatologists, plastics surgeons and ophthalmologists.

The valuations of Solta Medical Inc (NASDAQ:SLTM) have been pretty stagnant in the last few years. During the last few quarters shares have fluctuated between $2 and $3. While the valuations have remained stagnant, Solta has shown a significant revenue growth. The company revenues have increased from $110 million (2010) to $144 million (2012), growing by nearly 31%. Despite the revenue growth, gross margins have remained stable at around 62%. However, this growth has not been reflected in the bottom-line due to an approximately 100% increase in SG&A expenses to $104 million.

In the recent past Solta has become an attractive acquisition target. The stagnant price and lack of dividends indicate that a profitable acquisition should be the right option. However, the board of Solta has been resisting any such attempts. According to Voce Capital, the company has been actively trying to thwart acquisition attempts by interested parties. In its last week’s letter to the board, Voce has demanded that the board should formulate a special committee to evaluate M&A. The firm has also criticized the board for shareholder dissatisfaction and intentionally refusing good bids for Solta. The board is already low on investor confidence as the shareholders have rejected the Board’s proposal to double the shares outstanding to 200 million.

There are a number of parties interested in Solta Medical. There have been rumors that Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is interested in acquiring Solta. The company has already acquired a number of companies in the last year.

Page 1 of 2
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

The 10 Most Peaceful Countries in the World

5 Big Reasons Communism Failed

The 15 Most Famous Carl Icahn Quotes

10 Scary Animals that are Actually Harmless

The 8 Most Famous Singer-Actors in Entertainment

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!